Measured Wealth Private Client Group LLC Sells 8,369 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Measured Wealth Private Client Group LLC lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 60.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,562 shares of the biopharmaceutical company’s stock after selling 8,369 shares during the period. Measured Wealth Private Client Group LLC’s holdings in Gilead Sciences were worth $451,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of GILD. Independent Advisor Alliance lifted its holdings in Gilead Sciences by 118.4% during the third quarter. Independent Advisor Alliance now owns 14,378 shares of the biopharmaceutical company’s stock worth $1,077,000 after buying an additional 7,794 shares during the period. Eudaimonia Partners LLC lifted its holdings in Gilead Sciences by 6.4% during the third quarter. Eudaimonia Partners LLC now owns 3,053 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 183 shares during the period. Kowal Investment Group LLC lifted its holdings in Gilead Sciences by 3.5% during the third quarter. Kowal Investment Group LLC now owns 4,502 shares of the biopharmaceutical company’s stock worth $337,000 after buying an additional 151 shares during the period. Rovin Capital UT ADV lifted its holdings in Gilead Sciences by 83.9% during the third quarter. Rovin Capital UT ADV now owns 5,708 shares of the biopharmaceutical company’s stock worth $428,000 after buying an additional 2,604 shares during the period. Finally, Mastrapasqua Asset Management Inc. lifted its holdings in Gilead Sciences by 3.5% during the third quarter. Mastrapasqua Asset Management Inc. now owns 4,316 shares of the biopharmaceutical company’s stock worth $323,000 after buying an additional 145 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now directly owns 96,304 shares in the company, valued at approximately $7,026,339.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD traded down $0.55 during trading on Friday, reaching $64.78. 7,822,720 shares of the company traded hands, compared to its average volume of 7,345,331. The firm’s fifty day simple moving average is $70.55 and its 200 day simple moving average is $75.83. The stock has a market cap of $80.66 billion, a P/E ratio of 179.94, a PEG ratio of 1.31 and a beta of 0.22. Gilead Sciences, Inc. has a 12-month low of $64.33 and a 12-month high of $87.86. The company has a current ratio of 0.98, a quick ratio of 0.72 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion during the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The company’s revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the business posted $1.37 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 3.74 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be paid a dividend of $0.77 per share. The ex-dividend date is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.75%. Gilead Sciences’s payout ratio is currently 855.56%.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. TD Cowen reduced their price target on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Friday, April 26th. Cantor Fitzgerald reduced their price target on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 7th. UBS Group reduced their price target on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. HSBC raised Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target on the stock in a research report on Wednesday, April 24th. Finally, Royal Bank of Canada reduced their price target on Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating on the stock in a research report on Friday, April 26th. Eleven investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $83.69.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.